This article explores the complex roles of cytokine networks in the development and progression of autoimmune diseases.

Before you start treatment with Cosentyx, tell your doctor and pharmacist which prescription, over-the-counter, and other medications you take. By sharing this information with them, you may help ...

Cosentyx (secukinumab) is a prescription drug that’s used to treat conditions such as plaque psoriasis and psoriatic arthritis. Cosentyx is given as an injection under the skin or as an IV ...

Cosentyx is the only treatment approved in an IV formulation that specifically targets and blocks interleukin-17A (IL-17A). Plaque psoriasis affects 250 million people worldwide. Image: courtesy of ...

This approval makes Cosentyx the first interleukin-17A inhibitor and second biologic approved for hidradenitis suppurativa. Approval was supported by positive results from SUNSHINE and SUNRISE ...

If you design a logo or any custom T-shirt on Canva and want to download a transparent version of your design, here is how you can do that. Canva lets you download a transparent image or logo to ...

The approval was based on data from two phase 3 trials that evaluated the use of Cosentyx in patients 6 to 18 years of age with severe plaque ... of patients who achieved an Investigator’s Global ...

The US Food and Drug Administration has approved Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis in pediatric patients six years and older who are candidates for ...

respectively), 70% total Cosentyx vs 15% total placebo (N=43 and N=41, respectively) and Investigator's Global Assessment modified 2011 (IGA) "clear" or "almost clear" skin response (32% 75 mg vs 5% ...

Novartis NVS announced that the FDA has approved a label expansion of IL-17 inhibitor, Cosentyx (secukinumab). Cosentyx is now approved for the treatment of active non-radiographic axial ...